Showing results (41-50 of 588) with videos related to
Sort By:
Pageof 59
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B AtkinsSeminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B AtkinsJournal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinomaMichael B Atkins, Meredith Regan, David McDermottThe Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.Melanoma Management|September 8, 2018
NRAS mutant melanoma: an overview for the clinician for melanoma managementRussell W Jenkins, Ryan J SullivanJournal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T FlahertyExpert Review of Clinical Pharmacology|December 5, 2014
Dabrafenib in combination with trametinib for the treatment of metastatic melanomaMark M Awad, Ryan J SullivanAmerican Journal of Clinical Dermatology|February 7, 2020
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?Lauren B Banks, Ryan J SullivanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant MelanomaJustine V Cohen, Ryan J SullivanPageof 59